March 29 (Reuters) - Eli Lilly ( LLY ) will sign a $2

billion deal with Hong Kong-listed biotech Insilico Medicine

, which uses artificial intelligence for drug

discovery, the Financial Times reported on Sunday.

Lilly will acquire exclusive rights to sell a GLP-1 drug for

diabetes from Insilico Medicine, the FT report said, citing

sources familiar with the matter.

Reuters could not immediately verify the report.